Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals reported Q3 2022 net revenue of $99.1 million, significantly up from $12.1 million in Q3 2021. ARCALYST net revenue was $33.4 million, with promising long-term data showing a 98.2% risk reduction in recurrent pericarditis events beyond 18 months (Hazard Ratio = 0.018, p0.0001). The company anticipates ARCALYST full-year revenues of
Kiniksa Pharmaceuticals, Ltd. (KNSA) announced a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and corporate activities. Interested participants can access the call via Kiniksa's website or register for telephone participation. A replay will be available approximately 48 hours after the event. Kiniksa focuses on developing therapeutic medicines addressing significant unmet medical needs, with assets including ARCALYST, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has finalized a global license agreement with Roche and Genentech for the development of vixarelimab, a monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million upfront: $80 million within 30 days and $20 million post-delivery of drug supplies. Additionally, Kiniksa could earn up to $600 million in milestones and royalties based on sales. The company expects this funding to sustain its operations through at least 2025.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:55 p.m. ET. The management will engage in a fireside chat, showcasing the company’s commitment to addressing unmet medical needs through innovative biopharmaceuticals.
A live webcast will be available on Kiniksa’s website, with a replay accessible 48 hours after the event, ensuring broad outreach to investors and stakeholders.
Kiniksa Pharmaceuticals reported Q2 2022 net revenue of $27 million from ARCALYST, marking a significant increase from $7.7 million in Q2 2021. The company expects full-year ARCALYST revenue between $115 million and $130 million. An upfront payment of $100 million is anticipated from a global license agreement with Genentech for vixarelimab, which will support operations into at least 2025. Kiniksa's net loss narrowed to $20 million from $41.6 million year-over-year. The company plans to enhance its sales team in Q4 2022.
Kiniksa Pharmaceuticals (KNSA) has entered a global licensing agreement with Roche and Genentech for the development and commercialization of vixarelimab, a monoclonal antibody targeting OSMRβ. Kiniksa will receive $100 million upfront and is eligible for up to $600 million in future milestones, along with royalties on net sales. The deal focuses on fibrotic indications where OSMRβ plays a critical role. Kiniksa plans to use the non-dilutive capital to expand its ARCALYST cardiovascular franchise. This agreement highlights Kiniksa's commitment to addressing significant unmet medical needs.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will host a conference call and live webcast on August 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q2 2022 financial results and corporate activities. The live webcast will be available on the company's website, with a replay accessible about 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for significant unmet medical needs, with key portfolio assets including ARCALYST®, vixarelimab, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals reported Q1 2022 net revenue of $22.2 million from ARCALYST, contributing to total revenues of $32.2 million. The company anticipates full-year net revenue from ARCALYST between $115 million and $130 million and expects cash reserves to sustain operations through 2024. Kiniksa's strategic collaboration with Huadong Medicine is expected to yield potential milestone payments up to $640 million. Despite a net loss of $25.2 million, this is an improvement from the previous year's loss of $49.5 million.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will hold a conference call on May 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q1 2022 financial results and corporate activities. A live webcast will be available on their website, with a replay accessible 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases, with a portfolio that includes ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, targeting significant unmet medical needs through innovative biologic mechanisms.
Kiniksa Pharmaceuticals reported Q4 2021 net revenue of $18.7 million from ARCALYST, totaling $38.5 million for the full year. Profitability was achieved in Q4 2021. The company expects ARCALYST net revenue for 2022 to range from $115 million to $130 million. A strategic collaboration with Huadong Medicine is set to enhance the development of ARCALYST and mavrilimumab in the Asia Pacific. Kiniksa's Q4 2021 net loss narrowed to $36.3 million from $53.7 million year-over-year, while cash reserves stood at $182.2 million.